Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ALK peptide vaccine

A peptide cancer vaccine directed against the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential immunostimulatory and antineoplastic activities. Upon administration, ALK peptide vaccine may elicit a cytotoxic T-lymphocyte (CTL) response against ALK-expressing tumor cells. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

ALK peptide vaccine

Search NCI's Drug Dictionary